Why did Quest issue $1.85 billion in new debt?

The company intends to use the net proceeds mainly to fund the purchase price and related transaction costs of its pending LifeLabs, Inc. acquisition, with any remainder for general corporate purposes such as refinancing its $600 million 3.50% notes due 2025.

What happens to the notes if the LifeLabs deal falls through?

The 2027 and 2029 notes would be subject to a special mandatory redemption at 101% of principal plus accrued interest. The 2034 notes would remain outstanding, and their proceeds could then be used for general purposes, including a possible termination fee and partly funding the redemption.

What are the key dates investors should watch?

The LifeLabs Termination Date is November 2, 2024, which may be extended to no later than March 2, 2025. Interest on the notes is payable June 15 and December 15, beginning December 15, 2024.

Are the notes secured, and what protections do holders have?

The notes are senior unsecured obligations ranking equally with the company's other senior unsecured debt. The indenture limits certain liens, sale-leaseback transactions, and consolidations or asset transfers, and holders can require repurchase at 101% upon a change of control triggering event.

Does the By-Laws amendment affect shareholders materially?

The amendment is largely conforming: it adds officer exculpation as permitted by law to match a charter change approved by stockholders at the 2024 annual meeting. It is not expected to have a significant direct financial impact.

DGX 8-K: Material Agreements & Corporate Changes

01—Abstract

Summary

Summary of the 8-K filed August 19, 2024. Cited figures are marked; the original filing is the authoritative source.

On August 19, 2024, Quest Diagnostics (DGX) closed a $1.85 billion^a senior unsecured notes offering comprising $400 million of 4.600% notes due 2027, $600 million of 4.625% notes due 2029, and $850 million of 5.000% notes due 2034.

The company intends to use the net proceeds mainly to fund the purchase price and transaction costs of its pending acquisition of LifeLabs, Inc. and related entities, with the balance available for general corporate purposes, including potentially repaying $600 million^b of 3.50% senior notes due 2025. The 2027 and 2029 notes carry a special mandatory redemption at 101% of principal plus accrued interest if the LifeLabs acquisition is not consummated by the Termination Date (November 2, 2024, extendable to no later than March 2, 2025), or if Quest notifies the trustee it will not pursue the deal. The 2034 notes have no such feature and would remain outstanding in that scenario.

Proceeds from the 2034 notes would then fund general purposes, a possible LifeLabs termination fee, and part of the redemption payment. This structure means the financing largely de-risks the deal's funding but leaves a contingent cash obligation tied to deal completion. The filing also disclosed a board-approved amendment to the By-Laws (August 14, 2024) to add officer exculpation, conforming to a charter change approved by stockholders in May 2024.

The notes are governed by the 2001 indenture as supplemented, with customary covenants limiting certain liens, sale-leasebacks, and consolidations, and a 101%^c change-of-control put. The filing itself does not disclose financial metrics such as leverage or pro forma impact, so investors should review the company's periodic reports for those.

02—Key points

Key Highlights

Issued $1.85 billion of senior unsecured notes across three tranches: $400M due Dec 2027 (4.600%), $600M due Dec 2029 (4.625%), and $850M due Dec 2034 (5.000%).
Proceeds are primarily earmarked to fund the purchase price and transaction costs of the pending LifeLabs, Inc. acquisition.
The 2027 and 2029 notes require redemption at 101% of principal plus accrued interest if the LifeLabs acquisition is not completed; the 2034 notes do not.
LifeLabs termination date is November 2, 2024, extendable to no later than March 2, 2025, under the Equity Purchase Agreement.
Remaining proceeds may repay $600M of 3.50% senior notes due 2025, support working capital, capex, or acquisitions.
Indenture covenants limit certain liens, sale-leaseback transactions, and mergers or asset sales; a change of control triggers a 101% repurchase offer.
Board amended the By-Laws on August 14, 2024 to add officer exculpation, conforming to a 2024 stockholder-approved charter amendment.

03—Questions

Frequently Asked Questions

Why did Quest issue $1.85 billion in new debt?
The company intends to use the net proceeds mainly to fund the purchase price and related transaction costs of its pending LifeLabs, Inc. acquisition, with any remainder for general corporate purposes such as refinancing its $600 million 3.50% notes due 2025.
What happens to the notes if the LifeLabs deal falls through?
The 2027 and 2029 notes would be subject to a special mandatory redemption at 101% of principal plus accrued interest. The 2034 notes would remain outstanding, and their proceeds could then be used for general purposes, including a possible termination fee and partly funding the redemption.
What are the key dates investors should watch?
The LifeLabs Termination Date is November 2, 2024, which may be extended to no later than March 2, 2025. Interest on the notes is payable June 15 and December 15, beginning December 15, 2024.
Are the notes secured, and what protections do holders have?
The notes are senior unsecured obligations ranking equally with the company's other senior unsecured debt. The indenture limits certain liens, sale-leaseback transactions, and consolidations or asset transfers, and holders can require repurchase at 101% upon a change of control triggering event.
Does the By-Laws amendment affect shareholders materially?
The amendment is largely conforming: it adds officer exculpation as permitted by law to match a charter change approved by stockholders at the 2024 annual meeting. It is not expected to have a significant direct financial impact.

04—Continue

← View all 8-K filings